Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

UCB (0GD8)

  Print      Mail a friend       Annual reports

Tuesday 04 March, 2008


UCB: Early Data on Cimzia® from the WELCOME Stu...

First Presentation of Six-Week Data from the WELCOME Study at ECCO

Brussels, Belgium - 4 March 2008 - 7:00 am CET - Six-week data from
the WELCOME trial presented at the 3rd congress of the European
Crohn's and Colitis Organisation (ECCO) show Cimzia� (certolizumab
pegol), the first and only PEGylated anti-TNF-alpha, to be effective
in Crohn's patients who are intolerant, or are no longer responding
to infliximab.

This is the first presentation of the initial six-week induction
results from WELCOME, a 539-patient, Phase IIIb multicentre study of
the effects of Cimzia� on Crohn's patients for whom infliximab
treatment was not successful.  During this six-week induction stage,
all patients received 400mg of Cimzia� sub-cutaneous at Weeks 0, 2
and 4.  At Week 6, 61 percent of the patients had achieved the
primary endpoint of response, defined as a decrease in Crohn's
Disease Activity Index (CDAI)* score >=100 points from baseline. In
addition, 39 percent of the patients were in remission, defined as a
CDAI score <=150 points.[1]

"These induction results are very promising," commented study
investigator Professor Severine Vermeire of Katholieke Universiteit
Leuven, Belgium. "The WELCOME data show that certolizumab pegol could
be a treatment option for patients with Crohn's disease who are
refractory to other biological agents, showing consistent results
across all patient groups."

In the WELCOME study, Cimzia� has demonstrated a low incidence of
injection site pain* (less than 2 percent). The most commonly
occurring AEs were headache, nasopharyngitis, nausea, vomiting,
pyrexia and arthralgia.  The incidence of serious adverse events
(SAEs) was 7 percent and the most frequent SAEs involved
gastrointestinal disorders (5 percent) and infections and
infestations (2 percent).[2]

In September 2007, Cimzia� was approved in Switzerland for the
treatment of Crohn's disease and it was launched in January 2008.

* MedDRA Preferred term
About Cimzia� (certolizumab pegol)
Cimzia� was approved for the treatment of Crohn's Disease in
Switzerland in September 2007. In the European Union, the Committee
for Medicinal Products for Human Use (CHMP) has adopted a negative
opinion on the market authorisation application (MAA) for Cimzia� in
the treatment of patients with Crohn's disease. UCB utilised the
appeal process to request a CHMP re-examination of the submission. A
decision is expected during the first half of 2008.

Cimzia� has been studied in clinical settings for more than 10 years,
beginning with rheumatoid arthritis trials in 1998, and a rigorous
clinical trial program in Crohn's disease. Cimzia� has been studied
in more than 2000 Crohn's patients totalling over 2200 patient-years
of experience.

Cimzia� is the first and only PEGylated anti-TNF-alpha (Tumor
Necrosis Factor alpha). Cimzia� has a high affinity for human
TNF-alpha, selectively neutralising the pathophysiological effects of
TNF-alpha. Over the past decade, TNF-alpha has emerged as a major
target of basic research and clinical investigation. This cytokine
plays a key role in mediating pathological inflammation, and excess
TNF-alpha production has been directly implicated in a wide variety
of diseases.

The WELCOME (26-Week open-label trial Evaluating the clinical benefit
and tolerability of certoLizumab pegol induCtiOn and Maintenance in
patients suffering from CD with prior loss of response or intolErance
to infliximab) study consisted of an initial open-label induction
period of six weeks when patients received 400mg of Cimzia� at Weeks
0, 2 and 4.   After the induction period, 61 percent of patients had
reached the primary endpoint of response (defined as decrease in CDAI
score >=100 points from baseline). Responders at Week 6 were then
randomised to either Cimzia� 400mg maintenance every two or every
four weeks.[1]

Participants receiving a concomitant medication were:
immunosuppressant (46 percent); corticosteroids (38 percent) or
immunosuppressant and corticosteroids (18 percent).  Cimzia� was
consistently effective across all patient groups. The most common AEs
were headache, nasopharyngitis, nausea, vomiting, pyrexia and
arthralgia. The incidence of serious adverse events (SAEs) was 7
percent and the most frequent SAEs involved gastrointestinal
disorders (5 percent) and infections and infestations (2 percent).[2]

About Crohn's Disease
Crohn's disease is a chronic, progressive, destructive disorder that
causes inflammation of the gastrointestinal (GI) tract, most commonly
at the end of the small intestine (the ileum) and beginning of the
large intestine (the colon). If not effectively treated, it results
in the need for surgery. Crohn's disease usually affects young people
between the ages of 15 and 35, with approximately half a million
people affected in Europe alone.[3] People with Crohn's can
experience an ongoing cycle of flare-up and remission throughout
their lives. Together with ulcerative colitis, Crohn's disease is an
inflammatory bowel disease (IBD).[3],[4]

* The CDAI, or Crohn's Disease Activity Index, score measures the
severity of CD by taking into account a number of factors such as
intensity of symptoms, medication, and general well-being. Patients
with high scores have highly active Crohn's disease, while low scores
indicate the disease is less active.[5]

1. Vermeire S et al. Assessment of Certolizumab Pegol in the
Treatment of Crohn's Disease in Patients for Whom Infliximab
Treatment was not Successful: Open-label Induction Results from the
WELCOME Study. Oral presentation at the Congress of European Crohn's
and Colitis Organisation, Lyon, France, February 2008.
2. Data on file
3. Crohn's and Colitis Foundation of America. Disease Information
page ( accessed on 3 May 2007).
4. European Federation of Crohn's & Ulcerative Colitis Associations
Newsletter number 24 May 2006, page 19.
5. Best WR et al. Development of a Crohn's disease activity index.
National Cooperative Crohn's Disease Study. Gastroenterology; 1976,
70 (3): 439-444.

About UCB
UCB, Brussels, Belgium ( is a global leader in the
biopharmaceutical industry dedicated to the research, development and
commercialization of innovative pharmaceutical and biotechnology
products in the fields of central nervous system disorders,
allergy/respiratory diseases, immune and inflammatory disorders and
oncology. UCB focuses on securing a leading position in severe
disease categories. Employing around 12,000 people in over 40
countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB S.A.
is listed on the Euronext Brussels Exchange and, through its
affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG.
SCHWARZ PHARMA AG (Monheim, Germany) is a member of the UCB Group.

UCB Forward-Looking Statement
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.

Further information
Antje Witte, Vice-President Corporate Communications & Investor
Relations, UCB Group
T +32.2.559.9414, [email protected]

Horacio Cortes, Global Brand Manager IBD, UCB Group
T+32.496.12.68.52, [email protected]

Jenny Bickett, Senior Account Executive, Fleishman-Hillard
T+44.20.7395.7189, jenny.bicket[email protected]

For the pdf-version of this press release, please click on the link


a d v e r t i s e m e n t